Genworth Financial Inc Common Stock vs Liquidia Corporation Common Stock — how do they compare? Genworth Financial Inc Common Stock trades at $8.82 (market cap $3.33B), while Liquidia Corporation Common Stock trades at $34 (market cap $3.04B). The key difference: Genworth Financial Inc Common Stock and Liquidia Corporation Common Stock are close in size by market cap, and Genworth Financial Inc Common Stock is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Genworth Financial Inc Common Stock for 0 Days and Liquidia Corporation Common Stock for 0 Days on average.
| GNW | LQDA | |
|---|---|---|
Market Cap | $3.33B | $3.04B |
Volume | 3,324,561 | 21,111,778 |
Sector | Financials | Health |
52-Week High | $10.60 | $91.03 |
52-Week Low | $7.94 | $22.02 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $2.85B | $2.94B |
Signals from Pluang's Aura AI — not financial advice
Genworth Financial (GNW) trades at $8.89, down 1.77% today, with neutral technical signals and mixed fundamental performance. The company maintains stable revenue around $7.1-7.2B but faces margin pressure, with net income declining from $223M to $212M year-over-year. Recent Q2 2026 earnings beat expectations at $0.29 EPS, while the company expanded its share repurchase program by $500M in September 2026.
GNW presents value characteristics with low P/B (0.38) and P/S (0.49) ratios, but weak profitability metrics (ROE 2.42%) and analyst caution (70.59% hold rating) suggest limited near-term catalysts. Key risks include legacy insurance liabilities and competitive pressures, while the upcoming Q3 earnings on November 4 could provide directional clarity.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Genworth Financial, Inc. is a holding company that provides products and services related to aging and long-term care planning, and is the parent company of publicly traded mortgage insurer Enact Holdings, Inc.
Read more on GNW →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →